Lvguidingan

CAS No. 82351-05-1

Lvguidingan( Anticonvulsant 7903 | Lvguidingan | Chlocibutamine )

Catalog No. M17605 CAS No. 82351-05-1

Lvguidingan is an Anticonvulsant agent.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 41 In Stock
5MG 41 In Stock
10MG 65 In Stock
25MG 130 In Stock
50MG 192 In Stock
100MG 277 In Stock
200MG 393 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Lvguidingan
  • Note
    Research use only, not for human use.
  • Brief Description
    Lvguidingan is an Anticonvulsant agent.
  • Description
    Lvguidingan, also known as Anticonvulsant 7903, is an Anticonvulsant agent.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Anticonvulsant 7903 | Lvguidingan | Chlocibutamine
  • Pathway
    Chromatin/Epigenetic
  • Target
    COX
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    82351-05-1
  • Formula Weight
    272.17
  • Molecular Formula
    C13H15Cl2NO
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (459.27 mM)
  • SMILES
    CCC(C)NC(=O)/C=C/c1cc(c(cc1)Cl)Cl
  • Chemical Name
    (E)-N-butan-2-yl-3-(3,4-dichlorophenyl)prop-2-enamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Patejdl R, et al. Phenytoin inhibits contractions of rat gastrointestinal and portal vein smooth muscle by inhibiting calcium entry. Neurogastroenterol Motil. 2015 Oct;27(10):1453-65.
molnova catalog
related products
  • Talc

    Talc is a mineral composed of hydrated magnesium silicate.

  • Vedaprofen

    Vedaprofen inhibits COX-1 and reduces prostaglandin H2 synthesis with anti-inflammatory activities. Vedaprofen is an inhibitor of Escherichia coli sliding clamp with the IC50 of 222 μM and Ki of 131 μM.

  • Orientin

    Orientin may be regarded as a candidate therapeutic agent for treatment of vascular inflammatory diseases via inhibition of the HMGB1 signaling pathway.